A Phase II Study of TLK 286 [canfosfamide; TELCYTA; Telik] in Platinum Resistant Advanced Epithelial Ovarian Cancer.

Trial Profile

A Phase II Study of TLK 286 [canfosfamide; TELCYTA; Telik] in Platinum Resistant Advanced Epithelial Ovarian Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2013

At a glance

  • Drugs Canfosfamide (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Feb 2010 Actual end date (April 2004) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top